Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.